Revival of "unsuccessful" chemotherapeutics for highly glycolytic cancers?

Medical Hypotheses

Volumn 77, Issue 6, 2011, Pages 1150-

  Mathews, Edward Henry ^a   Liebenberg, Leon ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; GLUCOSE BLOOD LEVEL; GLYCOLYTIC CANCER; HUMAN; IMMUNE RESPONSE; LETTER; LEUKEMIA; METASTASIS; MICROENVIRONMENT; NEOPLASM; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASMS; RATS; SPECIES SPECIFICITY;

EID: 80755153595     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.09.020     Document Type: Letter

References (8)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer. Cell 2011, 144:646-674.
2. Zielinska E. Building a better mouse. The Scientist 2010, 24:34-38.
3. Watanabe M., et al. Internal environment for growth of cancer cells in mice. Health 2011, 3:238-244.
4. Watanabe M., et al. Internal environment in cancer patients. Health 2010, 2:781-788.
5. Mathews E.H., et al. High-glycolytic cancers and their interplay with the body's glucose demand and supply cycle. Med Hypotheses 2011, 76:157-165.
6. Seyfried T.N., Shelton L.M. Cancer as a metabolic disease. Nutr Metab 2010, 7:7.
7. Hollingshead M.G. Antitumor efficacy testing in rodents. JNCI 2008, 100:1500-1510.
8. Balis F.M., et al. Clinical drug development for childhood cancers. Clin Pharm Ther 2009, 85:127-129.